InsiderDirector
Kevin Tang Insider Trading Activity
Every SEC Form 4 transaction reported by Kevin Tang, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Is Kevin Tang buying or selling?
Kevin Tang reported 53 open-market buys ($190.5M) and 6 sells ($120.9M) across 59 Form 4 filings at 11 companies — a net buying position of $69.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 17, 2026)
Total Form 4 filings
59
SEC EDGAR
Companies
11
Buys (53)
$190.5M
Sells (6)
$120.9M
Insider sentiment
Net buyingNet insider flow of $69.6M in net buying, filed between Aug 15, 2018 – Jul 17, 2026.
Companies Kevin Tang files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | ODTOdonate Therapeutics, Inc. | 25 |
| 2 | LJPCLA JOLLA PHARMACEUTICAL CO | 9 |
| 3 | AUPHAurinia Pharmaceuticals Inc. | 5 |
| 4 | BOLDBoundless Bio, Inc. | 5 |
| 5 | TCRRTCR2 THERAPEUTICS INC. | 4 |
| 6 | APVOAptevo Therapeutics Inc. | 3 |
| 7 | RAINRain Oncology Inc. | 3 |
| 8 | HRTXHERON THERAPEUTICS, INC. /DE/ | 2 |
| 9 | FULCFulcrum Therapeutics, Inc. | 1 |
| 10 | JNCEJounce Therapeutics, Inc. | 1 |
Recent Kevin Tang transactions
| Date | Ticker | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jul 17, 2026 | BOLD | 10% Owner | Purchase | 64.0K | $155.6K |
| Jul 15, 2026 | FULC | 10% Owner | Purchase | 249.9K | $891.1K |
| Jul 13, 2026 | BOLD | 10% Owner | Purchase | 91.6K | $222.1K |
| Jul 9, 2026 | BOLD | 10% Owner | Purchase | 57.2K | $141.9K |
| Jul 2, 2026 | BOLD | 10% Owner | Purchase | 107.5K | $268.9K |
| Jun 29, 2026 | BOLD | 10% Owner | Purchase | 286.3K | $714.8K |
| Jun 3, 2026 | AUPH | Chief Executive Officer | Purchase | 814.6K | $12.5M |
| Mar 3, 2026 | AUPH | Director | Purchase | 900.0K | $12.7M |
| Aug 5, 2025 | AUPH | Director | Purchase | 1.3M | $13.6M |
| Mar 4, 2025 | AUPH | Director | Purchase | 1.6M | $12.7M |
| Dec 9, 2024 | AUPH | Director | Purchase | 1.2M | $10.8M |
| Sep 18, 2024 | OMIC | 10% Owner | Purchase | 122.4K | $1.8M |
| Dec 18, 2023 | RAIN | 10% Owner | Sale | 174.0K | $209.4K |
| Oct 13, 2023 | RAIN | 10% Owner | Purchase | 284.1K | $279.0K |
| Jun 1, 2023 | RAIN | 10% Owner | Purchase | 1.1M | $1.2M |
| May 31, 2023 | TCRR | 10% Owner | Purchase | 50.0K | $86.0K |
| May 15, 2023 | TCRR | 10% Owner | Purchase | 44.9K | $87.6K |
| May 10, 2023 | TCRR | 10% Owner | Purchase | 84.0K | $163.8K |
| May 5, 2023 | TCRR | 10% Owner | Purchase | 289.6K | $547.9K |
| Mar 15, 2023 | JNCE | 10% Owner | Purchase | 86.0K | $86.0K |
| Dec 2, 2021 | LJPC | Director, 10% Owner | Sale | 441.3K | $1.7M |
| Nov 26, 2021 | APVO | Other | Sale | 921.3K | $10.4M |
| Nov 22, 2021 | APVO | 10% Owner | Sale | 838.7K | $6.5M |
| Nov 19, 2021 | ODT | Chief Executive Officer | Sale | 2.7M | $5.7M |
| Jun 1, 2021 | LJPC | Director, 10% Owner | Purchase | 245.0K | $1.1M |
Showing the 25 most recent filings of 59. Screen every filing.
Kevin Tang insider trading FAQ
Is Kevin Tang buying or selling?
Across 59 SEC Form 4 filings, Kevin Tang reported 53 open-market purchases totaling $190.5M and 6 sales totaling $120.9M — a net buying position of $69.6M.
Which companies does Kevin Tang file Form 4s for?
Kevin Tang has reported insider transactions at 11 companies, most often Odonate Therapeutics, Inc. (ODT), LA JOLLA PHARMACEUTICAL CO (LJPC), Aurinia Pharmaceuticals Inc. (AUPH), Boundless Bio, Inc. (BOLD), TCR2 THERAPEUTICS INC. (TCRR).
How far back does Kevin Tang's filing history go?
Trabud holds Kevin Tang's SEC Form 4 filings from Aug 15, 2018 – Jul 17, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Kevin Tang's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Kevin Tang and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener